Purpose This article is aimed at describing the methodology of "ethical reasoning" that finally led TEDDYNoE (Taskforce in Europe for Drug Development for the Young) to propose the integration of international human rights law to develop coherent and exhaustive ethical recommendations on paediatric research at a European level. Methods A large number of ethical guidelines and texts of varying legal force existing in the field of clinical research and in particular related to paediatrics are analysed. Differences and non-coordinated implementation are pointed out. Results Differences, tensions or outright contradictions among the provisions of these texts can generate confusion leading to the adoption of different ethical standards across Europe. In this context, the real challenge is to ensure that each child involved in a clinical trial in the EU territory may rely directly on the same principles and rights. Taking international human rights law as the main starting point to develop a coherent framework for paediatric research that incorporates all the relevant ethical considerations and existing guidelines is a way of achieving this objective. Conclusions The implementation, at national and local level, of the "European Ethical Recommendations" (Eudralex 2008 vol. 10), based on international human rights law, seems to be the next step in facilitating a coordinated approach to the application of the Directive 2001/20/EC, as well as developing quality and ethically sound paediatric research.
Introduction
The main objective of clinical research is to develop generalizable knowledge to improve health and/or increase understanding of human biology. Ethical requirements for clinical research aim at minimizing the possibility of exploitation by ensuring that research subjects are not merely used but are treated with respect while they contribute to the social good [1] .
Clinical research on children raises many scientific and ethical concerns [2] . With respect to the paediatric population, there are significant deficits in the objective knowledge of quality and efficacy of current preventive measures, pharmacokinetics and pharmacodynamics of medications, appropriate dosage and application form for different age periods, and of the adequacy of deriving children's doses from adult studies [3] . The off-label or even off-licence use of medicine in children can have detrimental consequences in terms of unexpected adverse reactions and of access to the most up-to-date treatments.
Recently, the need to stimulate paediatric research in Europe has resulted in regulatory measures to facilitate and support clinical trials in this field [4] . The call for more medical research involving children has also raised the question whether the law as it stands strikes an appropriate balance between the need for clinical trials and the interests and rights of the child. While there is general agreement that children should be given special protection as research subjects, there are also concerns that too restrictive regulation may hinder research serving their long term health interests [5] .
Article 1 of the Universal Declaration of Human Rights expresses the basic right of all human beings to be free and equal in dignity and rights [6] . The main ethical and legal imperative of all paediatric activities is to do everything "in the best interests of children" [7] . The United Nations Convention on the Rights of the Child [7] asserts that children have the right to say what they think should happen when adults make decisions that affect them and to have their opinions taken into account (Article 12), have the right to get and share information (Article 13), have the right to think and believe what they want and practice their religion as long as they do not stop other people enjoying their rights (Article 14) and have the right to privacy (Article 16). All these assume growing levels of capacity to consent, which have to be taken seriously. As children develop, it should be the degree of their maturity which determines when they are regarded as fully competent and capable of autonomous decisions. This will differ from child to child.
Apart from the general requirements of research on human subjects such as an adequate informed consent, a balance between risks and benefits, additional rules and principles have been developed at the international and European level in order to protect the best interests of the children involved in clinical research. Furthermore, relevant guidelines can be derived from the UN Declaration on the Rights of the Child, whereby every child has the fundamental right to life and dignity and is entitled to optimal care, based on the scientific evaluation of preventive, diagnostic and therapeutic measures. Paediatric care includes the responsibility to achieve the highest level of knowledge; consideration of the child-specific somatic, mental and social development; and empathic and trustworthy communication with the child and parents [8] .
In this article we will describe the methodology of "ethical reasoning" that ultimately led TEDDYNoE (Task-force in Europe for Drug Development for the Young-Network of Excellence) to propose, during the consultation process [9], the integration of international human rights law in the "Ethical considerations for clinical trials performed in children", finally approved by the European Commission in 2008 [10] . This document aims at facilitating the conduct of paediatric clinical trials in the EU and at contributing to the protection of children involved.
Methodology

Ethical principles and guidelines
According to the main international declarations and guidelines [11] [12] [13] [14] [15] , all research involving human subjects should be conducted in accordance with three basic ethical principles, namely respect for persons, beneficence and justice.
Respect for persons incorporates at least two fundamental ethical considerations: (1) respect for autonomy, which requires that those who are capable of deliberation about their personal choices should be treated with respect for their capacity for self-determination; and (2) protection of persons with impaired or diminished autonomy, which requires that those who are dependent or vulnerable be afforded security against harm or abuse.
"Vulnerability" refers to a substantial incapacity to protect one's own interests owing to such impediments as lack of capability to give informed consent, lack of alternative means of obtaining medical care or other expensive necessities, or being a junior or subordinate member of a hierarchical group. Accordingly, special provision must be made for the protection of the rights and welfare of minors as vulnerable persons [16] .
Beneficence refers to the ethical obligation to maximize benefits and to minimize harms. This principle gives rise to norms requiring that the risks of research be reasonable in the light of the expected benefits, that the research design be sound, and that the investigators be competent both to conduct the research and to safeguard the welfare of the research subjects. Justice refers to the ethical obligation to treat each person in accordance with what is morally right and proper. In the field of research, the principle refers primarily to distributive justice, which requires the equitable distribution of both the burdens and the benefits of participation in research.
In the light of these principles, consensus is emerging concerning what elements are necessary requirements for the ethical conduct of clinical research. These include scientific value and validity, favourable risk-benefit ratio, fair subject selection, informed consent, independent review and respect for subjects [17] . So, to be ethical, clinical research must be valuable, meaning that it must evaluate a diagnostic or therapeutic intervention that could lead to improvements in health or well-being or test a hypothesis that can generate important knowledge about the structure or function of human biological systems, even if that knowledge does not have immediate practical ramifications [17, 18] .
Valuable research must be conducted in a methodologically rigorous manner. The methods must be valid and practically feasible: the research must have a clear scientific objective; it has to be designed using acceptable principles, methods and reliable practices; it must have sufficient power to definitively test the objective and offer a plausible data analysis plan. In addition, it must be possible to execute the proposed study [17, 18] . Paediatric research design should employ, wherever possible, child-friendly settings, personnel and procedures that limit invasiveness to a meaningful minimum [19] .
Scientific goals of the study have to be the primary basis for determining the groups and individuals that will be recruited and enrolled, both through the development of a strategy and specific inclusion and exclusion criteria that, in case of paediatric research, explicitly recognize the vulnerability of children [20] .
Clinical research can be justified only if, in accordance with the scientific aims of the study and the relevant standards of clinical practice, the potential risks to individual subjects are first identified and minimized. To this end, procedures which are consistent with sound research design and which do not necessarily expose subjects to risk should be used, and whenever appropriate, procedures already being performed on the subjects for diagnostic or treatment purposes should be adopted [18] . Secondly, the health-related potential benefits of the research to individual subjects are to be delineated and enhanced. Finally, the potential benefits to individual subjects and society have to be proportionate to or outweigh the risks.
In the evaluation of the expected impact of proposed research on an individual patient or a group, benefits can be of several kinds: advancing the patient's or society's interests, producing new knowledge of value to future patients or devising a policy which advances the common good. Risks are the estimates of probabilities or possibilities of injuring a patient or a group, for example producing harms that violate the interests of the research subjects. Harms may be financial, physical, emotional or spiritual, singly or in combination [20] .
When dealing with paediatric research it is necessary to be more risk averse and seek evidence of direct personal benefits or benefits to their own class of persons as a result of research participation. Benefits should be evaluated conservatively, whereas harms are assessed more broadly [21] . Benefits must be apparent to the individual child or to children in general or the research cannot be pursued even if it involves minimal risk. Harms must be assessed from the perspective of the child and be sensitive to the child's lesser capacity to understand what is going on, the effects of disruptions, inconvenience and novel situations on the child and family [21] .
The threshold for harm in children uses the standard of "minimal risk" and "minimal burden" beyond which specific justification for such risk/burden exposure must be present. The research bears a minimal risk if, with regard to the nature and scale of the intervention, it is to be expected that it will result, at the most, in a very slight and temporary negative impact on the health of the person concerned. It bears a minimal burden if it is to be expected that the discomfort will be, at the most, temporary and very slight for the person concerned. In assessing the burden for an individual, a person enjoying the special confidence of the person concerned shall assess the burden where appropriate [22] .
Nobody should be forced to engage in activities inconsistent with his or her own values, interests and preferences. Freely given informed consent is the foundation of contemporary ethics in clinical research. It can be withdrawn at any moment without any prejudice, liability or discrimination against the participants in the research. Consent requires that the individual be competent. Due to developmental and cognitive limitations, children are not yet competent persons, meaning that they are not capable of providing legal consent to research participation [23] . In the absence of the capacity to provide consent, permission for research participation must be sought from a proxy, taking into account the best interests of the child [24, 26] . Legal representatives have to put foremost choices that preserve well-being and maintain the capacity of the child to ultimately develop into an autonomous decision maker [25] . A child's assent or dissent has to be considered as reflecting a lower level of decision-making capability that is developmentally determined. The research should not start or be discontinued if the child raises objections or resistance. Children must be solicited in an appropriate manner sensitive to their current cognitive and developmental abilities. Well-crafted age appropriate informational materials should aid investigators in explaining to potential child research participants exactly which elements of their medical care are research and therefore optional [27, 28] .
Another essential requirement for ethical conduct of research is the independent review of clinical protocols by an ethics committee. This provides a mechanism for thirdparty validation separate from the vested interests of investigators that ensures that scientific and ethical standard are being met. It is a means of keeping in check potential conflicts of interest, protecting the welfare of subjects, allowing for transparency and finally providing public (i.e. social) accountability that is reassuring to potential subjects [21] . To guarantee the well-being and rights of children participating in a clinical research, protocols have to be endorsed by an ethics committee with paediatric expertise or after taking advice in clinical, ethical and psychological problems in the field of paediatrics [29] .
Finally, providing participants in clinical research additional information about the effect of the intervention or the subject's clinical condition learned from the research, protecting confidentiality and monitoring well-being are key aspects of ethical research to guarantee the respect for persons and their autonomy, in the light of the principles of beneficence and non-maleficence.
Legal framework
At the European level, the Oviedo Convention [34] and Clinical Trial Directive 2001/20/EC [29] establish that the accepted basis for the conduct of clinical trials in humans is founded on the protection of human rights (namely the right to life, to physical and mental integrity and to privacy) as well as human dignity, that is "the cardinal principle of the legal norms relating to bioethics" [30] .
As a direct corollary of human dignity, these documents affirm the primacy of the human being over science and society and emphasize two fundamental ideas: first, that science is not an end in itself but only a means for improving the welfare of individuals and society; second, that people should not be reduced to mere instruments for the benefit of science.
Additionally, through the incorporation of the ICH Guidance on Good Clinical Practice and its effective adoption as binding law, the Directive can be seen as affording protection to individual research participants and especially to vulnerable subjects (e.g. children). To this end, Directive 2001/20/EC devotes a specific article (Article 4) to minors' protection.
Nevertheless, even if all the European countries implemented Directive 2001/20/EC with respect to clinical research practices in paediatrics, there exists a "regulatory gap" or rather a "regulatory conflict" not only among ethical and legal frameworks at the European level but, most of all, between the European ethical/legal frameworks (Directive 2001/20/EC, Oviedo Convention, Additional Protocol on Biomedical research, etc.) and national regulations [31] .
Many differences exist in Europe related to the guarantees of children rights, to the protection of minors involved in clinical trials across Europe as well as to the ethics reviews of paediatric protocols [32, 33] . Some countries go beyond the requirements of the Directive. For instance they place more importance on the will of the minors (Spain) or consider their will necessary to involve them in clinical trials (Denmark, Estonia and the Netherlands). The expression of will is accepted at different age limits (12 years in Spain, 15-17 years in Denmark, 7-17 years in Estonia, 12 years in the Netherlands) [31, 32] .
With reference to acceptable risk and burden for children involved in clinical research, Greece, Ireland, Italy and Belgium would seem to follow the more liberal Directive (requiring "minimising" risk and burden, also if there is only group benefit). The Netherlands, France and Finland seem to follow the stricter Additional Protocol on Biomedical Research [22] , which requires there to be minimal risk and burden if there is only group benefit [33, [46] [47] [48] [49] [50] .
Furthermore, the wide range of situations due to a nocoordinate Directive 2001/20/EC implementation, the great differences in cultural and economic environments, and the large number of texts of differing legal force existing in the field of clinical research, with special reference to paediatrics, can cause difficulties in imposing penalties on research that violates human rights of minors in the name of medical progress. In this context, it was imperative to have a systematic and coherent framework for evaluating clinical studies that incorporates all the relevant ethical considerations.
International human rights law and European ethical recommendations
In 2008, the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC, chaired by the European Commission approved the document "Ethical Considerations for Clinical Trials on Medicinal Products with the Paediatric Population" [10] . In accordance with proposals submitted by TEDDYNoE during the consultation process [9], these recommendations integrate principles contained in all the international/European ethical/legal sources relevant for biomedical research and consistent with international human rights law [6, 7, 11-16, 22, 29, 34-41] .
The purpose was to ensure that each minor involved in a clinical trial in the EU territory may appeal directly to the same principles and rights in order to apply the principle of equality of treatment that is an implicit milestone in building a Europe-wide democratic society, based on the respect of fundamental rights.
"The human rights framework" provides a more useful approach for analyzing and responding to modern public health challenges than any framework thus far available within the biomedical tradition [42] . Since the adoption of the Universal Declaration of Human Rights in 1948, a large number of international instruments have been adopted to ensure the unconditional respect for the human person in very diverse contexts. Furthermore, the existing human rights system, with its extensive body of international standards and wide range of follow-up mechanisms, represents one of the most remarkable achievements of our time. Therefore, it is important to make use of this rich normative and institutional set-up in order to protect people from harm in the field of biomedicine [52] .
All the above-mentioned sources [6, 7, 11-16, 22, 29, 34-41] address ethical issues related to medicine, life sciences and associated technologies as applied to children, taking into account their social, legal and environmental dimensions, as well as the necessity to protect individuals and groups of special vulnerability (such as children) and to respect the personal integrity of such individuals.
Since, in value systems recognized in Europe, the respect for fundamental rights constitutes an indivisible obligation for the public authority to fulfill, the methodological approach aimed at integrating human rights law seemed to be particularly useful for recognizing the importance of freedom of research and the benefits derived from scientific and technological developments, while providing a universal framework of principles and procedures to guide the EU and member states in the formulation of their legislation, policies or other instruments in the field of bioethics and paediatric clinical research.
The methodology of using international human rights ethical reasoning in developing a European ethical framework for paediatric research is based on the awareness of interrelation and complementarity of the principles contained in all the ethical/legal European/international sources as well as of the pluralistic and non-hierarchical relationship existing between these principles. The extent to which principles referred to in various documents (both legal and ethical instruments) are taken into account in national or regional legislation within the EU is variable. They overlap in many areas, but some give greater precision on certain points whilst on others there are differences in approach.
In case of tensions or outright contradictions among the provisions of the various guidelines related to clinical research [43] , conflicts should be solved by finding a balance between competing principles, taking into account the "highest ethical standards" (as standards providing more guarantees) with the aim to protect the health and rights of the child. The legal value of the source or a culturally sensitive interpretation of the principle shall be considered as well.
In such a sensitive field as bioethics and clinical research, where socio-cultural, philosophical and religious traditions come into play, using the human rights framework should facilitate the formulation of universal standards because international human rights law is based on the assumption that some basic rights transcend cultural diversity.
So, the mentioned methodology aimed at grounding ethical reasoning in human rights provided ethical recommendations with an opportunity to be accepted by different cultures and traditions, even outside Europe. Ethical recommendations are expected to facilitate a coordinated approach to the application of the Clinical Trial Directive across the EU with special reference to paediatric research and are also relevant to clinical trials conducted in non-EU countries, especially developing countries.
These recommendations integrate the Clinical Trial Directive provisions and clarify the process of assessing the benefit and risk balance, the process of information and consent/assent according to age groups and maturity level of minors and the process of ethical review of paediatric protocols. They also deal with individual data protection and insurance issues. The main principles are, first, that children may not be included in clinical trials if the same results can be obtained using adults. Second, whenever possible the research should have a direct benefit for the children involved; without such a benefit, the risks must be strictly limited and every effort must be made to reduce pain, discomfort and fear. Third, parents or guardians must be fully informed and have given consent for the participation of their child; minors should be involved in the informed consent process in proportion to age and degree of maturity.
In particular, with reference to the consent/assent process, new EC recommendations specify that separate information sheets for adults and children, and separate consent and assent forms should be used in order to provide information in language and wording appropriate to age and psychological and intellectual maturity. Assent, like consent, is a continuous process and should be sought during the trial as well. The information process provided to the child and the child's response should be documented. Every effort should be made to understand and respect differences of opinion between the child and his/her parents or legal representative. Strong and definitive objections from the child should be respected.
With reference to paediatric expertise to be included in the ethics committee in charge of reviewing protocols, it is underlined that this expertise goes beyond having dealt with children and could be defined on the basis of education and experience related to the various child development, ethics and psychosocial aspects. Furthermore, the qualifications and expertise of the experts and the members of the ethics committee should be documented and appended to its opinion.
Finally, ethical standards, principles and requirements contained in the European ethics recommendations could be reinterpreted, refined and revised with changes in science and experience. Nevertheless, as human rights sets the standard in bioethics, according to Article 27 of the Universal Declaration on Bioethics and Human Rights, any limits to the application of these principles need to be consistent with the international human rights law [37] .
Conclusions
The ethical conduct of clinical research in children is challenged by the inherent vulnerability of this population. Children should enjoy the benefits of clinical research, but they should be protected from harms to their health and well-being. Even if these two objectives seem to be partly incompatible [2, 51] , it is important to balance them in order to meet the specific therapeutic needs of the paediatric population, without subjecting this population to unnecessary trials. Thus, trials involving children are on trial [44] .
The European Paediatric Regulation provides rewards, incentives and obligations for pharmaceutical companies to facilitate the development and availability of high-quality medicines for children. Meanwhile, high ethical standards, education and training of investigators in good clinical practice as well as the protection of health and rights of children involved in clinical trials are needed. The ethical obligation to assess interventions in children should override drug profitability projections [45] .
Thus, the real challenge is to translate ethical principles into clinical research and to establish procedures that are consistent with human rights international law, both ethically sound and culturally sensitive, although there may be times when these two requirements appear to be in conflict.
In this context, the European ethics recommendations, providing an ethical framework based on international human rights law, lead to explicit, heightened universal standards of ethical propriety that seek to balance the real need to conduct research and the need to protect children from the exploitation of their vulnerability.
It is our collective responsibility to promote the application of these updated rules. To this aim efforts are needed at both the regulatory and scientific levels to implement these ethical standards at national and local levels. It is also essential to increase the awareness of the ethical aspects of paediatric research and to promote public debates, education and training initiatives involving main stakeholders (e.g. sponsors, investigators, ethics committees, regulatory bodies, patient associations).
This methodological approach is crucial from the perspective of the internationalization of research, which creates new responsibilities, particularly regarding research carried out under the scientific and financial control of developed nations in developing countries. To develop sound ethical principles intertwined with international human rights law and facilitate their implementation globally would contribute to the development of research of high quality that respects the fundamental rights of each individual and is a source of progress for the health and welfare of everyone around the globe.
